Clinical Trial Update: PhaseⅠClinical Trial of 24-valent Pneumococcal Polysaccharide Conjugate Vaccine [EARLY_Phase 1]

View source ↗

Summary

Completion of an early-phase 1 trial evaluating a 24-valent pneumococcal polysaccharide conjugate vaccine for pneumococcal pneumonia.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pneumococcal Pneumonia

Drugs mentioned

• 24-valent pneumococcal polysaccharide conjugate vaccine (pneumococcal polysaccharide conjugate vaccine (24-valent))

Snippet

Sponsor: Jiangsu Province Centers for Disease Control and Prevention | Conditions: Streptococcus Pneumoniae Pneumonia | EARLY_Phase 1 | Status: COMPLETED